TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (R2) has been approved in Europe as the first and only bispecific-based, chemotherapy-free option for second-line relapsed or refractory follicular lymphoma. The approval is based on Phase 3 EPCORE® FL-1 results, supporting a differentiated treatment profile versus prior chemo-based regimens. Impact is supportive for biotech sentiment, though the excerpt provides no financial figures or quantified efficacy outcomes.
TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (R2) has been approved in Europe as the first and only bispecific-based, chemotherapy-free option for second-line relapsed or refractory follicular lymphoma. The approval is based on Phase 3 EPCORE® FL-1 results, supporting a differentiated treatment profile versus prior chemo-based regimens. Impact is supportive for biotech sentiment, though the excerpt provides no financial figures or quantified efficacy outcomes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
